Plain-English translation of NCT05979051 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to see if it can help treat EGPA, a rare condition where your immune system attacks small and medium-sized blood vessels, causing inflammation and damage. The study will compare this medication to a placebo (an inactive treatment) to understand whether the medication is safe and effective at reducing symptoms and helping patients need lower doses of steroids.
People with EGPA often have flare-ups even while taking steroids, and high doses of steroids can cause serious side effects over time. Researchers believe this medication might help control the disease better and allow patients to take lower doses of steroids.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the new medication () or a placebo injection. You will continue taking your regular prednisone dose as prescribed. Throughout the study, you'll have clinic visits where the research team will check how you're doing, run blood tests, and assess whether your EGPA symptoms are improving. The study involves both a Phase 2 portion (to test safety and initial effectiveness) and a Phase 3 portion (to confirm the results in a larger group of patients).
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
China